Company intelligence

CNTA

Centessa Pharmaceuticals plc · NASDAQ · Healthcare

Price$40.50+0.00% · +$0.00

Market cap6.27BEquity value

P / E-22.6Trailing ratio

Volume0Latest session

Market data

CNTA price chart

TradingView

Related signals

1 min delayed

Browse public CNTA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CNTAMar 31, 2026+43.58% since signal

Eli Lilly to acquire Centessa Pharmaceuticals in strategic deal

Eli Lilly has announced its acquisition of Centessa Pharmaceuticals for $38 per share, which could reach $47 with contingent value rights tied to regulatory milestones. This acquisition enhances Lilly's neuroscience and sleep disorder portfolio, solidifying its commitment to innovative therapies in the field. The deal is expected to close in Q3 2026, subject to approvals.

View signal analysis

CNTAMar 31, 2026+43.58% since signal

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion

Eli Lilly has announced it will acquire Centessa Pharmaceuticals for $38.00 per share, totaling approximately $6.3 billion. This acquisition includes contingent value rights tied to FDA approvals of Centessa's promising sleep disorder treatments, which could enhance Lilly's portfolio and revenue stream in the neuroscience sector.

View signal analysis

Research